Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Quest Partners LLC

Quest Partners LLC grew its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 54.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,318 shares of the company’s stock after acquiring an additional 1,522 shares during the quarter. Quest Partners LLC’s holdings in Castle Biosciences were worth $123,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of CSTL. Marshall Wace LLP increased its holdings in shares of Castle Biosciences by 116.5% in the second quarter. Marshall Wace LLP now owns 212,036 shares of the company’s stock valued at $4,616,000 after purchasing an additional 114,104 shares during the period. Harbor Capital Advisors Inc. raised its position in Castle Biosciences by 249.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock worth $3,020,000 after buying an additional 99,001 shares during the last quarter. Renaissance Technologies LLC raised its position in Castle Biosciences by 47.3% during the 2nd quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock worth $6,564,000 after buying an additional 96,800 shares during the last quarter. Lisanti Capital Growth LLC acquired a new stake in Castle Biosciences during the 2nd quarter valued at approximately $2,102,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Castle Biosciences by 33.0% in the 2nd quarter. Acadian Asset Management LLC now owns 280,497 shares of the company’s stock valued at $6,101,000 after acquiring an additional 69,673 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on CSTL shares. Stephens reissued an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a report on Tuesday, August 6th. Scotiabank lifted their price objective on Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Lake Street Capital upped their target price on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group lifted their price target on Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Finally, KeyCorp boosted their price target on Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences presently has a consensus rating of “Buy” and a consensus price target of $37.88.

Castle Biosciences Stock Down 0.4 %

Castle Biosciences stock opened at $30.44 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The stock has a market capitalization of $852.53 million, a PE ratio of 152.20 and a beta of 0.99. The business has a 50 day simple moving average of $30.94 and a 200-day simple moving average of $26.63. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.14. The company had revenue of $85.78 million during the quarter, compared to analyst estimates of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same quarter in the previous year, the firm earned ($0.26) EPS. On average, analysts anticipate that Castle Biosciences, Inc. will post -0.08 EPS for the current fiscal year.

Insider Activity at Castle Biosciences

In other news, insider Tobin W. Juvenal sold 3,507 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the sale, the insider now owns 54,178 shares of the company’s stock, valued at $1,926,569.68. This represents a 6.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 986 shares of the stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $28.73, for a total transaction of $28,327.78. Following the completion of the sale, the insider now owns 94,622 shares of the company’s stock, valued at $2,718,490.06. This trade represents a 1.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,213 shares of company stock valued at $752,673. 7.20% of the stock is owned by corporate insiders.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.